Meglumine gamma linolenate

Drug Profile

Meglumine gamma linolenate

Alternative Names: Megla; Meglumine gamma linolenic acid; Meglumine GLA; SC 101i

Latest Information Update: 22 Jan 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scotia Pharmaceuticals [CEASED]
  • Class Antineoplastics; Hexosamines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bladder cancer

Most Recent Events

  • 22 Jan 2002 Discontinued-II for Bladder cancer in United Kingdom (Intratumoural)
  • 19 Oct 2000 Phase-II clinical trials for Bladder cancer in United Kingdom (Intratumoural)
  • 19 Oct 2000 A clinical study in patients with bladder cancer has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top